ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Belgian biotech firm Galapagos has agreed to sell its contract research organization (CRO) Fidelta to the Polish CRO Selvita for about $38 million. Based in Croatia, Fidelta employs more than 150 chemists and other scientists who provide discovery services to drug industry customers. Galapagos sold its other CROs, BioFocus and Argenta, to Charles River Laboratories in 2014.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter